AzurRX Biopharma, which is developing non-systemic biologics for gastrointestinal disorders, filed on Wednesday with the SEC to raise up to $15 million in an initial public offering.
The Brooklyn, NY-based company was founded in 2007 and plans to list on the Nasdaq under the symbol AZRX. WallachBeth Capital and Network 1 Financial Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
